Literature DB >> 20118978

Chemotherapy: dose-dense treatment for triple-negative breast cancer.

Eitan Amir, Alberto Ocana, Orit Freedman, Mark Clemons, Bostjan Seruga.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20118978     DOI： 10.1038/nrclinonc.2009.231

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Tumor size, sensitivity to therapy, and design of treatment schedules.

Authors:  L Norton; R Simon
Journal:  Cancer Treat Rep       Date:  1977-10

2.  Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.

Authors:  Marco Venturini; Lucia Del Mastro; Enrico Aitini; Editta Baldini; Cinzia Caroti; Antonio Contu; Franco Testore; Fulvio Brema; Paolo Pronzato; Giovanna Cavazzini; Mario Roberto Sertoli; Giuseppe Canavese; Riccardo Rosso; Paolo Bruzzi
Journal:  J Natl Cancer Inst       Date:  2005-12-07       Impact factor: 13.506

3.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

Authors:  Marc L Citron; Donald A Berry; Constance Cirrincione; Clifford Hudis; Eric P Winer; William J Gradishar; Nancy E Davidson; Silvana Martino; Robert Livingston; James N Ingle; Edith A Perez; John Carpenter; David Hurd; James F Holland; Barbara L Smith; Carolyn I Sartor; Eleanor H Leung; Jeffrey Abrams; Richard L Schilsky; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-02-13       Impact factor: 44.544

4.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Authors:  Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman B Muss; Larry Norton; Clifford Hudis; Eric P Winer
Journal:  JAMA       Date:  2006-04-12       Impact factor: 56.272

5.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

6.  Combination chemotherapy as an adjuvant treatment in operable breast cancer.

Authors:  G Bonadonna; E Brusamolino; P Valagussa; A Rossi; L Brugnatelli; C Brambilla; M De Lena; G Tancini; E Bajetta; R Musumeci; U Veronesi
Journal:  N Engl J Med       Date:  1976-02-19       Impact factor: 91.245

7.  Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.

Authors:  Michele De Laurentiis; Giuseppe Cancello; Diego D'Agostino; Mario Giuliano; Antonio Giordano; Emilia Montagna; Rossella Lauria; Valeria Forestieri; Angela Esposito; Lucrezia Silvestro; Roberta Pennacchio; Carmen Criscitiello; Agnese Montanino; Gennaro Limite; Angelo Raffaele Bianco; Sabino De Placido
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

8.  Weekly paclitaxel in the adjuvant treatment of breast cancer.

Authors:  Joseph A Sparano; Molin Wang; Silvana Martino; Vicky Jones; Edith A Perez; Tom Saphner; Antonio C Wolff; George W Sledge; William C Wood; Nancy E Davidson
Journal:  N Engl J Med       Date:  2008-04-17       Impact factor: 91.245

9.  The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.

Authors:  Chau Dang; Monica Fornier; Steven Sugarman; Tiffany Troso-Sandoval; Diana Lake; Gabriella D'Andrea; Andrew Seidman; Nancy Sklarin; Maura Dickler; Violante Currie; Theresa Gilewski; Mary Ellen Moynahan; Pamela Drullinsky; Mark Robson; Carolyn Wasserheit-Leiblich; Nancy Mills; Richard Steingart; Katherine Panageas; Larry Norton; Clifford Hudis
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

10.  HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients.

Authors:  L Del Mastro; P Bruzzi; G Nicolò; G Cavazzini; A Contu; M D'Amico; A Lavarello; F Testore; B Castagneto; E Aitini; L Perdelli; C Bighin; R Rosso; Marco Venturini
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640
  10 in total
  10 in total

Review 1.  Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines.

Authors:  A A Joy; M Ghosh; R Fernandes; M J Clemons
Journal:  Curr Oncol       Date:  2015-03       Impact factor: 3.677

2.  G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist.

Authors:  Tali Voloshin; Svetlana Gingis-Velitski; Rotem Bril; Liat Benayoun; Michal Munster; Chloe Milsom; Shan Man; Robert S Kerbel; Yuval Shaked
Journal:  Blood       Date:  2011-06-17       Impact factor: 22.113

3.  Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients.

Authors:  Carmel Jacobs; Mark Clemons; Sasha Mazzarello; Brian Hutton; Anil A Joy; Muriel Brackstone; Orit Freedman; Lisa Vandermeer; Mohammed Ibrahim; Dean Fergusson; John Hilton
Journal:  Support Care Cancer       Date:  2017-01-27       Impact factor: 3.603

4.  Diagnostic and prognostic significance of serum apolipoprotein C-I in triple-negative breast cancer based on mass spectrometry.

Authors:  Dongjian Song; Lifang Yue; Junjie Zhang; Shanshan Ma; Wei Zhao; Fei Guo; Yingzhong Fan; Heying Yang; Qiuliang Liu; Da Zhang; Ziqiang Xia; Pan Qin; Jia Jia; Ming Yue; Jiekai Yu; Shu Zheng; Fuquan Yang; Jiaxiang Wang
Journal:  Cancer Biol Ther       Date:  2016-06-03       Impact factor: 4.742

5.  Wnt modulates MCL1 to control cell survival in triple negative breast cancer.

Authors:  Lixin Yang; Aldwin Apollo Perez; Sayuri Fujie; Charles Warden; Jie Li; Yafan Wang; Bryan Yung; Yun-Ru Chen; Xiyong Liu; Hang Zhang; Shu Zheng; Zheng Liu; David Ann; Yun Yen
Journal:  BMC Cancer       Date:  2014-02-24       Impact factor: 4.430

6.  Lectin RCA-I specifically binds to metastasis-associated cell surface glycans in triple-negative breast cancer.

Authors:  Shu-Min Zhou; Li Cheng; Shu-Juan Guo; Yang Wang; Daniel M Czajkowsky; Huafang Gao; Xiao-Fang Hu; Sheng-Ce Tao
Journal:  Breast Cancer Res       Date:  2015-03-11       Impact factor: 6.466

7.  Inverse agonist of estrogen-related receptor α suppresses the growth of triple negative breast cancer cells through ROS generation and interaction with multiple cell signaling pathways.

Authors:  Ying-Min Wu; Zhuo-Jia Chen; Guan-Min Jiang; Kun-Shui Zhang; Qiao Liu; Shu-Wei Liang; Yan Zhou; Hong-Bin Huang; Jun Du; Hong-Sheng Wang
Journal:  Oncotarget       Date:  2016-03-15

Review 8.  Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer-A Review of Molecular Characterisation, Therapeutic Targets and Future Trends.

Authors:  Karen Pinilla; Lynsey M Drewett; Rebecca Lucey; Jean E Abraham
Journal:  Front Oncol       Date:  2022-08-08       Impact factor: 5.738

9.  Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155).

Authors:  Tasaduq Hussain Wani; Goutam Chowdhury; Anindita Chakrabarty
Journal:  RSC Med Chem       Date:  2021-02-15

10.  Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial).

Authors:  John Hilton; Carol Stober; Sasha Mazzarello; Lisa Vandermeer; Dean Fergusson; Brian Hutton; Mark Clemons
Journal:  PLoS One       Date:  2018-07-24       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.